C4 Therapeutics Inc
CCCC
Market Cap$428.07M
Close$
$-1.21
119.2% downside
Current Fair Value
119.2% downsideOvervalued by 119.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $428.07 Million |
|---|---|
| Enterprise Value | $245.36 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.67 |
| Beta | 0.0 |
| Outstanding Shares | 68,600,669 |
| Avg 30 Day Volume | 1,310,506 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.23 |
|---|---|
| PEG | 49.42 |
| Price to Sales | - |
| Price to Book Ratio | 2.1 |
| Enterprise Value to Revenue | 11.82 |
| Enterprise Value to EBIT | -1.76 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
ESG Score
No data
About C4 Therapeutics Inc
99 employeesC4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and o...